Can modeling of HIV treatment processes improve outcomes? Capitalizing on an operations research approach to the global pandemic by Xiong, Wei et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Health Services Research
Open Access Correspondence
Can modeling of HIV treatment processes improve outcomes? 
Capitalizing on an operations research approach to the global 
pandemic
Wei Xiong†1, Nathaniel Hupert*†1,2,3, Eric B Hollingsworth†1, 
Megan E O'Brien†4, Jessica Fast†4 and William R Rodriguez†5,6
Address: 1Department of Public Health, Weill Medical College, Cornell University, New York, NY, USA, 2Department of Medicine, Weill Medical 
College, Cornell University, New York, NY, USA, 3NewYork-Presbyterian Hopital, New York, NY, USA, 4Clinton Foundation HIV/AIDS Initiative 
(CHAI), Quincy, MA, USA, 5Global Health Delivery Project, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA and 
6Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA, USA
Email: Wei Xiong - wmz2001@med.cornell.edu; Nathaniel Hupert* - nah2005@med.cornell.edu; 
Eric B Hollingsworth - ebh2001@med.cornell.edu; Megan E O'Brien - mobrien@clintonfoundation.org; 
Jessica Fast - jfast@clintonfoundation.org; William R Rodriguez - wrodriguez@partners.org
* Corresponding author    †Equal contributors
Abstract
Background: Mathematical modeling has been applied to a range of policy-level decisions on
resource allocation for HIV care and treatment. We describe the application of classic operations
research (OR) techniques to address logistical and resource management challenges in HIV
treatment scale-up activities in resource-limited countries.
Methods: We review and categorize several of the major logistical and operational problems
encountered over the last decade in the global scale-up of HIV care and antiretroviral treatment
for people with AIDS. While there are unique features of HIV care and treatment that pose
significant challenges to effective modeling and service improvement, we identify several analogous
OR-based solutions that have been developed in the service, industrial, and health sectors.
Results: HIV treatment scale-up includes many processes that are amenable to mathematical and
simulation modeling, including forecasting future demand for services; locating and sizing facilities
for maximal efficiency; and determining optimal staffing levels at clinical centers. Optimization of
clinical and logistical processes through modeling may improve outcomes, but successful OR-based
interventions will require contextualization of response strategies, including appreciation of both
existing health care systems and limitations in local health workforces.
Conclusion: The modeling techniques developed in the engineering field of operations research
have wide potential application to the variety of logistical problems encountered in HIV treatment
scale-up in resource-limited settings. Increasing the number of cross-disciplinary collaborations
between engineering and public health will help speed the appropriate development and application
of these tools.
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1. Background
Three decades after its start, the global HIV epidemic is
now the target of perhaps the most ambitious global
health program ever conceived, dwarfing in its complexity
and requirement for sustainability the campaign to eradi-
cate smallpox, which is widely considered one of the
crowning public health achievements of the late 20th cen-
tury. In the last ten years, the campaign to scale up HIV
care and antiretroviral therapy (ART) for millions of peo-
ple with AIDS living in resource-limited countries has
gained substantial commitments in financing [e.g., the
Global Fund to Fight AIDS, Tuberculosis and Malaria
(GFATM), the World Bank's Multi-Country AIDS Program
(MAP), the United States' President's Emergency Plan for
AIDS Relief (PEPFAR) program, private donors such as the
Bill & Melinda Gates Foundation], operational support
[e.g., Joint United Nations Programme on HIV
(UNAIDS), World Health Organization (WHO)], and
procurement support [e.g., the Clinton Foundation HIV/
AIDS Initiative (CHAI)].
While over 30 million people are living with HIV and over
2 million new infections are estimated to occur each year,
HIV care and treatment has expanded significantly in this
decade: it is estimated that by December 2006 more than
2 million people, or 28% of people living with HIV in
low- and middle-income countries, had access to antiret-
roviral treatment, a substantial improvement from 2%
coverage just three years earlier [1-3]. These figures con-
firm the success of early efforts to scale up global HIV
treatment, but serious obstacles to continued expansion
remain to be addressed. For example, approximately 95%
of HIV-infected people live in developing countries [4],
which typically face challenges of underfunding, limited
materiel resources, and severe human resource shortages
in the health sector [5]. Increasing ART coverage in these
settings will require sophisticated logistics and managerial
skill at every point of health service delivery from the local
to the transnational levels. The operational challenges
include developing adequate and efficient physical infra-
structures, providing long-term financial sustainability,
and eliminating constraints to treatment capacity, most
notably in human resources and pharmaceuticals and
diagnostics supply chains.
These challenges were noted in a recent review of the PEP-
FAR program: "The continuing challenge for the U.S. Glo-
bal AIDS Initiative is to simultaneously maintain the
urgency and intensity that have allowed it to support a
substantial expansion of HIV/AIDS services in a relatively
short time while also placing greater emphasis on long-
term strategic planning and increasing the attention and
resources directed to capacity building for sustainability
[5]." Below we describe one scientific field that holds
promise to help maintain the acceleration of HIV treat-
ment scale-up: the discipline of Operations Research
(OR), the applied science of maximizing the effective use
of limited resources [6].
OR offers a plethora of modeling techniques that may be
used to assess, operationalize, and evaluate HIV treatment
scale-up activities with the goal of transforming existing
health systems in target countries to achieve efficiency and
sustainability in the provision of life-long, effective treat-
ment for people with HIV. While OR techniques and
models have been successfully utilized in many areas to
maximize the effective use of scarce resources, the applica-
tion of mathematical modeling to HIV scale-up to date
typically has focused on policy-level issues (e.g., program
costs) as opposed to operational-level issues [7-10]. We
believe that application of these tools to practical deci-
sions about resource allocation and health care organiza-
tion may increase the success of existing programs and
help to expand access to HIV care and treatment in
resource-limited countries. This paper reviews current
challenges to expanded HIV care and treatment that may
be amenable to OR-based interventions; discusses poten-
tial benefits and pitfalls of the use of applied models in
longitudinal HIV care and treatment; and concludes with
a summary to guide the future application of OR to scale-
up activities.
2. The practical challenges of HIV treatment 
scale-up
Global scale-up of HIV care and treatment involves com-
plex issues in logistics, the science that deals with the pro-
curement, distribution, maintenance, and replacement of
materiel and personnel [11]. During the WHO's "3 by 5"
campaign, many stakeholders provided logistical support,
including procurement and distribution of antiretroviral
drugs and other supplies, creation of infrastructure, and
the training and recruitment of the healthcare work force.
Not surprisingly, significant logistical challenges remain.
Here we focus on three categories of logistical challenges
that are key barriers to achieving universal access to HIV
prevention and treatment: pharmaceutical supply chain
management, laboratory service infrastructure and plan-
ning, and healthcare workforce development.
2.1 Pharmaceutical supply chain management
The increasing demand of global AIDS treatment poses
unprecedented challenges for supply chain management,
since each point of dispensing antiretroviral (ARV) drugs
(i.e., clinic, hospital, community outreach worker) must
have access to a customized and predictable supply of
ARVs and other drugs at all times. The robustness of this
supply chain is essential to the success of any AIDS treat-
ment program, and it must take into account a number of
unique features and constraints of antiretroviral treat-
ment.BMC Health Services Research 2008, 8:166 http://www.biomedcentral.com/1472-6963/8/166
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At the clinical level, HIV treatment scale-up in most low-
and middle-income countries embraces the WHO's "pub-
lic health approach" to ART use, where treatment regi-
mens are standardized according to widely accepted
consensus guidelines [12]. Unavoidably, customization
of care takes place at multiple points, from country-level
protocols that adapted WHO guideline to regional needs,
to patient-level adjustments in treatment due to co-mor-
bidities, such as tuberculosis, or adverse events, such as
stavudine-related neuropathy. The degree of customiza-
tion varies considerably from program to program; in Bra-
zil, for example, clinicians have access to most
antiretroviral medications, while in Malawi individual
health facilities receive shipments of a prescribed, narrow
formulary [13,14]. In all settings, key patient-level varia-
bles (e.g., the presence of anemia or neuropathy) should
trigger a range of possible drug substitutions that will lead
to measurable differences in demand at an individual
clinic or regional level of care. The ideal pharmaceutical
supply chain that is responsive to these needs will have, at
a minimum, the following features [15]:
(1) an inventory control system
(2) a logistics management information system
(3) a storage system, and
(4) a distribution system
Major efforts are underway to assist countries and care
providers with all four of these aspects of supply chain
development and management. To be successful, these
efforts need to overcome a number of constraints, some of
which are unique to ART and some of which apply gener-
ally to medical material management. ARVs are notable
for their short shelf-lives and, for some – particularly the
non-heat stable form of protease inhibitors – the need for
a "cold chain" to provide refrigeration. Standard ART for-
mularies for children and adults require multi-drug regi-
mens that often involve products manufactured by more
than one manufacturer, potentially complicating efforts
to insure not only continuity but parity of supplies. For
many other medical conditions, including many infec-
tious diseases, drug substitution due to stockouts (e.g.,
prescribing one antibiotic for another that is not availa-
ble) is common and has little clinical impact. Stockouts of
ARVs, in contrast, can have important health conse-
quences because of the limited availability and medical
compatibility of substitute drugs, and the serious risks of
intermittent adherence in terms of viral resistance. Finally,
although the cost of first-line ARVs has declined dramati-
cally in recent years, ART is one of the most expensive glo-
bal public health interventions ever undertaken,
amplifying the impact of supply chain inefficiencies [16].
The ideal supply chain will synchronize aggregate patient-
level drug demand with the flow of pharmaceuticals from
suppliers, reducing inventory investment along the chain,
and improving patient care by minimizing supply short-
ages. Sustainable and flexible supply chains with capacity
for forecasting, procurement, distribution, and informa-
tion sharing can improve drug utilization and decrease
waste, yet even the best-designed supply chains may expe-
rience interruptions caused by shortage, damage, drug
expiration, and miscommunication. Optimizing supply
chain management (SCM) has been a central focus of the
OR community since the concept of SCM first appeared in
the engineering literature in the mid-1980's, bridging pre-
viously independent lines of research into inventory con-
trol, product management, and industrial processes
control [17,18].
2.2 Laboratory service infrastructure and planning
Laboratory-based diagnostic services are necessary for the
proper identification of HIV disease and are used for lon-
gitudinal monitoring of all HIV-infected patients. Labora-
tory data – notably the CD4 cell count – can guide the
timing of therapeutic interventions and ensure the maxi-
mum level of safety and monitoring for treatment failure
when antiretroviral drugs are being delivered [1]. How-
ever, access to hospital-based laboratory facilities for ART
monitoring is a challenge in most resource-limited coun-
tries; to compound matters, outpatient laboratory services
especially are scarce in rural areas [19]. Despite the impor-
tance of laboratory capacity for the effective delivery of
ART, there have been only a handful of systematic
approaches developed and implemented in resource-lim-
ited countries to ensure sustainable, practical laboratory
service for HIV treatment scale-up [20].
As with the creation of effective ARV supply chains, the
development and support of clinical laboratory infrastruc-
ture to support ART scale-up in resource-limited countries
will need to address a number of logistical constraints.
Foremost among these is the expense of currently availa-
ble HIV laboratory testing equipment and reagents, their
need for regular maintenance, and the skilled labor force
required both to operate and maintain them. Currently,
many countries operate a decentralized model of labora-
tory capacity with little interaction between laboratories at
national, regional, and district levels [20]. In some of
these countries, many facilities dispensing ART already
experience shortages of functioning equipment, reagents,
and technicians to conduct regular maintenance and tech-
nical support. When faced with insufficient laboratory
capacity, health planners have two options: add addi-
tional laboratory capacity by purchasing more equip-
ment, or increase the utilization of equipments that have
already been purchased and are either idle or underuti-
lized, often through the implementation of a sampleBMC Health Services Research 2008, 8:166 http://www.biomedcentral.com/1472-6963/8/166
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transport network. Ancillary costs, such as those of rea-
gents, typically are tied in complex ways to machine utili-
zation, so the cost of an idle machine may be more than
simply its inconvenience or the downstream costs of lost
clinical services.
After ARV costs, building laboratory capacity is the most
capital-intensive component of global ART scale-up. In
addition to technical training and patient education, it
involves equipment selection, human resource training
for operations and maintenance, reagent selection and
purchase, and transportation infrastructure for moving
samples and results between points of care and laboratory
machines [21]. Less well described is the need for labora-
tory information technology infrastructure, to link sam-
ples and results to patients, and return the laboratory data
from the testing facilities to the clinicians at the sites of
care. It is possible that, with proper development of infra-
structure for training, preventive maintenance, and
repairs, many countries currently experiencing laboratory
service interruptions have sufficient laboratory capacity
for ART scale-up. If this is the case, in the short term,
rather than adding more machines, Ministries of Health
may be better served by development of a flexible and effi-
cient sample referral network to bring samples to the
instruments which are currently under-utilized, thereby
ensuring the direct and indirect benefits from using that
laboratory capacity at its maximum potential. In the long
term, investments in laboratory infrastructure and the
development of more appropriate, point-of-care devices
will be needed to replace potentially unreliable specimen
transport networks and shorten the cycle time of labora-
tory-based information back to the clinical encounter,
which can be as long as several weeks in many settings.
2.3 Healthcare workforce development
In addition to supply chain management and laboratory
capacity, the challenge of training and retention of health-
care workers is a third critical logistical aspect of HIV serv-
ice delivery that has been widely identified as perhaps the
single largest constraint on global treatment scale-up. This
challenge is greatest in regions worst-hit by the disease
due to multiple factors including direct workforce effects
of the pandemic (i.e., death and disability), international
financing policies restricting investment in the health sec-
tor, and the "brain drain" – outmigration of qualified
practitioners toward urban areas and higher wage coun-
tries in Europe and North America [22]. Human resources
affect both the scope and speed of treatment scale-up in
most resource-limited countries, yet few countries have a
"comprehensive training plan, a clear assessment of ongo-
ing training needs, a plan to operationalize training on a
large scale, or adequate funds budgeted for training [23]."
The spectrum of healthcare workers encompasses doctors,
nurses, pharmacists, lab technicians, phlebotomists,
counselors, program managers, and community health
workers, as well as other ancillary staff. Successful scale-up
involves relatively complex planning for recruiting and
training a mix of healthcare workers providing a wide
range of services, which are influenced significantly by the
HIV care delivery model chosen by a country or region. In
a setting where the demand for healthcare workers enor-
mously exceeds the available resources, OR approaches
may be able to provide technical support to program
mangers to evaluate the capacity of existing systems and
estimate the minimal required amount of healthcare
workers for effective scale-up. Furthermore, OR models
can be used to evaluate different models of care and to
provide insight into the impact on quality and capacity of
HIV clinics adopting different HIV care delivery models.
3. Applying Operations Research to Scale-up
Millions of people living in resource-limited countries
need life-long medical care, now including ART, posing a
fundamental logistical challenge for effective HIV care
and treatment and raising challenges to the technical fea-
sibility of the goal of universal access. Increased funding
alone, though necessary, will not solve these issues, since
it is not only the procurement of resources but the man-
agement of those resources at the point of need that will
determine the success or failure of local HIV interven-
tions. This means there is an urgent need for strategies to
build and maintain efficient systems of care and pharma-
ceutical delivery, laboratory capacity, and healthcare
worker recruitment and training. In the remainder of this
paper, we show how these areas may benefit from the
application of operations research methods, as well as
anticipated barriers to this application.
3.1 What is Operations Research?
In the world of HIV treatment and prevention, the term
"operations research" or, more commonly, "operational
research" has been applied to a field of study that is some-
what different from what engineers and management sci-
entists mean by OR. To date, most HIV-related operations
research studies have focused on the description, analysis,
and improvement of day-to-day activities or "operations"
of HIV program [24]. These operations include training,
education, counseling and testing, commodity logistics,
hospital and clinic activities, and community- and home-
based care, among others. HIV-focused operations
research therefore has been used to describe most studies
that quantify some aspect of HIV clinic operations and their
associated impact on patient outcomes. Because of this
inclusive meaning, most observational field studies of
ART clinic operations, for example, would be considered
HIV-related operations research.BMC Health Services Research 2008, 8:166 http://www.biomedcentral.com/1472-6963/8/166
Page 5 of 10
(page number not for citation purposes)
By contrast, the engineering/management science disci-
pline of OR refers to the application of a collection of
mathematical techniques used to model real-world sys-
tems and gain insight into their operations. The Institute
for Operations Research and the Management Sciences
(INFORMS) – the largest professional society for special-
ists in the field of operations research – defines operations
research as "the discipline of applying advanced analytical
methods to help make better decisions." This umbrella
concept of operational research covers many analytic
approaches and methods, such as mathematical program-
ming, queueing theory, simulation modeling, decision
analysis, and forecasting methods. Techniques from other
fields such as statistics and computer science are also
employed by operations researchers to assist with deci-
sion making.
OR approaches have been widely implemented for ana-
lyzing problems in complex real-life systems. These meth-
ods have provided informative insights and yielded
substantial economical benefit [25], suggesting that OR
models can be used in the following (sometimes overlap-
ping) areas:
￿ The optimal allocation of scarce resources subject to a
large number of constraints (e.g., HIV funding allocation
to treatment and prevention programs)
￿ The search for efficient solutions among a vast multitude
of alternative choices (e.g., clinical and laboratory infra-
structure and capacity building)
￿ The analysis of dynamic systems characterized by fluctu-
ating inputs and out puts (e.g., care delivery model evalu-
ation and clinical activities analysis)
￿ The use of inferential processes to derive insights from
multivariate statistical analyses (e.g., quality assurance
across multiple care delivery and supply chain systems)
￿ Computer simulation of intricate economic and physi-
cal systems
The logistical problems arising in HIV treatment scale-up
are precisely the types of problems that OR methodolo-
gies were designed to address. The challenge of scaling up
HIV treatment in the developing world is unprecedented,
and as such will certainly require novel solutions and new
ways of thinking. However, certain core aspects of logisti-
cal problems in scale-up have been addressed successfully
in other industries and settings through the use of OR
methodologies.
3.2 How can operations research improve global HIV 
outcomes?
Decision makers may employ OR models to address the
range of uncertainties in HIV interventions, from assess-
ing treatment capacity requirements and the uncertainty
in demand for ARVs, to the optimal staffing of treatment
clinics. We categorize these logistics-related uses of OR
into two types according to the scope and planning hori-
zon considered: policy-level uses and operational-level
uses.
3.2.1 Policy level decision support
Policy level decisions often involve the acquisition or allo-
cation of durable resources intended to be utilized over a
long time horizon. For example, decisions related to pro-
gram funding or resource allocation, healthcare workforce
planning, prevention strategy or delivery model selection,
typically comprise strategic-level policy decisions, and
these present a clear role for the application of operations
research methodologies.
• Resource Allocation
Mathematical programming models have been developed
to address efficiency and equity in the HIV funding alloca-
tion process on the national, state, or municipal levels in
the United States [8,10,26,27]. These models seek to
determine the best allocation that minimizes the number
of potential infections for a given period of time, given an
available budget and equity considerations. Recent assess-
ments of ART in developing countries have focused on
modeling macro-level distribution of resources for health
care delivery. For example, one study examined the
impact of healthcare facilities location, catchment area
size, and other demographic parameters on an optimally
equitable allocation [27]. However, real-world HIV
resource allocation typically is driven by a number of cri-
teria aside from cost-effectiveness and equity considera-
tions. OR-based analysis and modeling represent an
evaluation methodology with which multiple competing
alternatives can be weighed from multiple perspectives,
including those of equity or efficiency.
• Healthcare Workforce Planning
Perhaps the most glaring deficiency in resource-limited
settings is the lack of healthcare workers for the 30+ mil-
lion people living with HIV. A variety of OR techniques
are available to address problems in human resource
planning, hiring, and training in knowledge-intensive
operations under uncertainty [28-30]. Based on data col-
lected on specific tasks in the delivery of care through
process analysis and time-motion studies, OR models can
be used to identify the optimal mix of different cadres of
healthcare workers for efficient scale-up. Once targets are
set for scale-up, models can also be used to estimate the
demand for human resources linked to local care deliveryBMC Health Services Research 2008, 8:166 http://www.biomedcentral.com/1472-6963/8/166
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models. More important, these estimates will contribute
to understanding the capability of existing systems and
identify the ideal combination of training methodologies
to prepare for scale-up [23].
• Laboratory Infrastructure Planning
The healthcare system infrastructure in most of sub-Saha-
ran Africa has been suffering from decades of underfund-
ing and declining capacity [31]. Adequate financing is a
fundamental requirement for building laboratory infra-
structure. Yet the development of a national laboratory
network into one that improves the utilization of existing
laboratory capacity may result in substantial financial sav-
ings. This type of problem can be formulated as the tradi-
tional capacitated facility location problem (CFLP), which
has been studied extensively in the OR literature [25].
CFLP has numerous applications in warehouse location
and distribution planning, telecommunication network
design, and manufacturing production planning [32].
Given accessible laboratory facilities and their processing
capacity, ministries of health can use models to identify
the most cost-effective way to re-distribute test demand
among laboratory facilities and decide where to locate
new laboratory equipment for future scale-up.
3.2.2 Operational level decision support
Operational level decisions are local decisions related to
situations where operations must be undertaken or exe-
cuted in a short time frame in response to system status or
changes (e.g. order quantity, equipment breakdown,
weather or road changes). For instance, material managers
have a difficult time determining how much safety stock
to hold and when to initiate orders for material from
upstream sites, given the various degrees of uncertainty in
supply and demand that impact their operations. Model-
based support systems can help to anticipate variability
and optimize purchasing.
• Demand Forecasting
Forecasting is the process of estimating how much of a
selected product will be needed in a given period of time.
A number of tools have been developed to assist minis-
tries of health and transnational groups in forecasting
resource demand (e.g., Bertozzi, et al. [6]). However, fore-
casts are generally made using historical data; available
data are limited since most countries started to implement
their standard guidelines and protocols only in the last
several years. For example, simple linear regression mod-
els have been used for global ARV demand forecasts,
though they have been based on very limited observations
[33]. Furthermore, commodity demands for HIV treat-
ment programs can be highly unpredictable, because of
the dynamic nature of the problem: evolving treatment
protocols and patient populations requiring longitudinal
follow-up with changing drug demand patterns. To
improve the forecasts, attempts have been made to use a
simulation approach to obtain insight into the dynamics
of disease progression among existing and expected
patient population, and thereby identify trends of
resource usage, provide forecasts of drug demands, or
even estimate the uncertainty in a forecast [34].
• Supply Chain Design
A supply chain is a network of facilities that performs the
functions of procurement of material, transformation of
material to intermediate and finished products, and distri-
bution of finished products to customers [35]. A major
challenge in managing an efficient supply chain is to min-
imize, to an appropriate extent, inventories and costs
along the chain while maximizing customer service per-
formance. OR has a long history of providing supply
chain managers the decision support they need to design
and improve a supply chain. Many industries have gained
tremendous benefit from OR efforts to improve supply
chain efficiency. For example, the potential savings from
reengineering supply chain design ranges from $14 bil-
lion for the food service industry to $30 billion for the
grocery industry [36]. However, the design and imple-
mentation of an effective HIV drug supply chain poses fur-
ther challenges for both researchers and practitioners.
The strong emphasis of recent treatment scale-up efforts is
to place management of pharmaceutical procurement and
distribution within the primary healthcare system [5].
Treatment of HIV alone usually requires the simultaneous
high-level availability (95%) of at least three drugs, each
with relatively short shelf-life. In addition, side-effects of
ARVs, especially in the early phase of treatment, occur
with calculable but varying frequency, leading to shifting
requirements for alternative first-line medications
throughout the treatment coverage area. Importantly, HIV
is a chronic illness associated with specific conditions that
also require treatment, such as tuberculosis or cervical
cancer, as well as with routine longitudinal care in a pri-
mary health setting. A recent report describes the adapta-
tion of tuberculosis medication procurement systems
with large (e.g., three-month) 'buffer stocks" in order to
insure consistent availability of HIV medications, but
such systems may not remain financially or logistically
viable as treatment volumes increase. The unique charac-
teristics of HIV treatment – requiring an increasing and
uninterrupted supply of multiple medications in chang-
ing drug combinations – are amenable to models devel-
oped specifically for the integration of local, regional, and
country-level supply chain management.
• Service Benchmarking
When applying the same pubic health strategies for HIV
treatment programs, outcomes in terms of logistic issues
will not necessarily be the same because of diversified set-BMC Health Services Research 2008, 8:166 http://www.biomedcentral.com/1472-6963/8/166
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tings across the globe. For example, the amount of inven-
tory kept at various locations of the supply chain is an
important measure of performance. However, inventories
at various points may have different cost structures, vary-
ing as a result of service level requirements and supply
responsiveness. It is often inappropriate to use the
amounts of inventories as a direct performance metric for
different supply chains and different points in a supply
chain. Furthermore, the uncertainty of supply chains in
different countries and regions may differ dramatically in
terms of their structures, drug supplies, security, transpor-
tation and other infrastructures, etc. Therefore, in the
process of scale-up, it is inappropriate to directly adopt
successful inventory control rules from other programs. In
order to have a better understanding and assessment of
existing logistic activities, it is desirable to use OR models
to determine the optimal performance needed to support
a service target at various locations given the nature of the
supply chain.
• Service Integration
The most cogent critique of many global health programs
has been that their implementation involves the delivery
of services in vertical silos that by themselves may
improve narrowly defined outcomes, but that as a whole
enable a fractured system of health care, and perpetuate
both inefficiencies and inequities in health care delivery.
One oft recognized aspect of the global effort to deliver
HIV services is that, because HIV is inherently a longitudi-
nal health condition best treated at a community primary
care level, the effective scale-up of HIV care will necessar-
ily target not only the disease but also prevailing vertical
systems of care, addressing their inefficiencies and inequi-
ties. OR has been used in other industries to recognize the
misallocation of resources that results from taking a local
perspective to a larger problem, and to redirect resources
into an integrated model of service delivery. OR thus pro-
vides another tool for policy makers to analyze the bene-
fits of integrating services at a primary care level.
3.3 Example: A simulation model for capacity planning at 
HIV clinics
In 2005–6, we created a stochastic simulation model to
assist capacity planning for HIV treatment clinics, dia-
gramed in Figure 1[37,38]. This simulation model was
designed to capture patient characteristics (WHO stage,
CD4 count distribution, attrition), disease progression
(CD4 decline), treatment protocols, human resource uti-
lization, and the competition for limited resources in a
single clinic. We modeled the clinic as a set of intercon-
nected work stations representing different working cad-
res (e.g., clerk, nurse, doctor). An enrollment plan of the
clinic is used as one input to the simulation. Patients
scheduled by the enrollment plan, as well as random
arrivals, are created by the simulation program and are
routed to the clinic, visiting different stations in based on
health status (which the model assigns to each patient
based on inputted values and evidence-based assump-
tions) and country-specific treatment protocols (based on
health ministry publications). Clinical details ranging
from the treatment process, logistics, staffing, to the
demand for drugs, are considered in the clinic visit. After
each visit, patients may come back or be lost to follow-up
visits. During this time, each individual patients disease
progression or biological reactions to treatment are mod-
eled. In this way, the simulation program can be used to
represent aggregate patient visit dynamics to determine
maximal enrollment and visit capacity under steady-state
clinic operations in the setting of user-manipulated
resource constraints.
In early 2008, we created a simulation model to provide a
service benchmarking framework, quantifying the physi-
cian time saved in a task-shifting program in Rwanda that
gave primary HIV treatment responsibility to nurses work-
ing under physician supervision [39]. Using data from
this pilot program in three health centers, we were able to
estimate the person-hour savings of a critical resource, in
this case physicians, by modeling the impact of varying
provider assignment, the number and duration of visits,
and physician time spent supporting nursing staff. We
estimated that if task-shifting were scaled up to the
national level it would reduce the demand on public-sec-
tor physicians for HIV services by 78%. The analysis sug-
gests that implementation of such a program could allow
the government of Rwanda to scale-up HIV treatment
without overburdening this component of its existing
healthcare system.
By quantifying the outcomes of task-shifting and other
programmatic changes in HIV care and treatment, models
like these can assist planners in analyzing and optimizing
future medical resource allocation. Similar tools can also
provide forecasts for key resources, including staffing,
space, drug volumes, laboratory kits and equipment to
support operational decisions such as the choice of treat-
ment protocols.
3.4 Barriers to Adoption of OR Methodologies
The relative absence of OR methodologies from global
HIV treatment scale-up activities, especially at the opera-
tional level, suggests that barriers exist to their implemen-
tation. These are likely to include technical complexity of
some of the applications (e.g., involving extensive data
analysis and computer-based modeling) and the need for
outside content experts to assist local governments and
their technical support agencies in the appropriate appli-
cation of various methodologies to specific problems.
More fundamentally, OR-based assessments require
investment in the collection, storage, and accessibility ofBMC Health Services Research 2008, 8:166 http://www.biomedcentral.com/1472-6963/8/166
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Schematic diagram of simulation model of HIV clinic operations Figure 1
Schematic diagram of simulation model of HIV clinic operations.
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valid, current data to yield accurate and applicable conclu-
sions. Funding of this type of operations-related data col-
lection has not always been prioritized in the rush to scale
up "emergency" treatment; whether this was the intention
of major funding organizations (rather than simply a con-
sequence of public health planners and practitioners over-
whelmed by immediate treatment needs) is under debate
[5]. Clearly, development of an OR workforce that is more
cognizant of the specific needs and limitations of working
in a health setting – especially in resource-limited settings
– can only help this situation. Consequently, one concrete
action that may speed the application of OR methodolo-
gies to HIV scale up will be "cross-training" of engineers
in public health and of public health and medical profes-
sionals in health systems engineering, either through joint
degree programs, special concentrations in existing pro-
grams, or post-graduate professional training.
4. Discussion
Operations research, the applied field of engineering that
is focused on the efficient use of scarce resources, holds
great promise to assist in efforts to craft effective and suc-
cessful scale-up of HIV care and AIDS treatment in
resource-limited countries. We have highlighted several
areas that parallel HIV scale-up activities and have bene-
fited from OR analyses. However, a number of obstacles
to the wide adoption of OR approaches in resource-lim-
ited settings, where there are considerable differences in
terms of decision making processes when compared to
developed countries, remain. A direct transposition of OR
techniques and approaches from this setting to another
will no doubt encounter many difficulties and may pro-
duce misleading results. It is also necessary to take into
account the environments in which OR projects are to be
carried out. Ethical, cultural, and political considerations,
which go beyond maximizing the cost-effectiveness objec-
tives, need to be considered carefully. Furthermore, as
noted in a recent review of the PEPFAR program, the gen-
eral lack of outcomes and operational data – which is
being remedied in many programs – is a serious hin-
drance to carrying out certain OR projects, such as fore-
casting [5].
In addition to the potential impediments in the field, to
date only limited funding has been available for opera-
tions-related work in scale-up, and what monies are avail-
able for this line of investigation and intervention
typically have been underutilized. GFATM, for example,
allows up to 10% of each grant to be allocated for opera-
tions research, but this provision is rarely used by coun-
tries and the research community is rarely represented on
Country Coordinating Mechanisms (CCMs) [40]. The
recent Sydney Declaration, supporting the allocation of
10% of HIV global programming funding on research
related to operations, has highlighted the need for and
benefits of OR and related study, echoing the results of the
evaluation carried out on the first years of the PEPFAR
program [5].
5. Conclusion
We stand at a critical moment in the global campaign to
scale up treatment for HIV-infected people, one in which
the magnitude of the remaining task threatens to over-
whelm the hard-fought gains that have brought treat-
ments to millions who recently had none. This paper
highlights the potential application of classic operations
research approaches to a variety of logistical issues that lie
at the heart of the scale-up process. HIV-related opera-
tional research has provided ministries of health, non-
governmental organizations, public health professionals,
and clinic managers with a better understanding of impact
and cost-effectiveness of various intervention and treat-
ment programs, as well as quantitative data about clinic
capacity, performance and other types of outcomes. The
engineering field of OR, with its toolbox of systematic
quantitative approaches, can provide additional tech-
niques to understand the data unearthed by engaging in
and reporting from clinical operations. We believe that
using these analytical techniques will allow clinic manag-
ers to get even more utility out of their operational
research, and will provide insight into management strat-
egies that can minimize the cost of operations while max-
imizing clinicians' ability to provide high-quality medical
care.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
WX, NH, MEO, and WRR conceived of the concept of the
paper. WX and NH wrote the first draft and all authors
contributed to that and to subsequent drafts of the paper.
Acknowledgements
The authors acknowledge the contributions of Elizabeth McCarthy to the 
content of this article. The authors acknowledge contributions of Jack 
Muckstadt, PhD, to the concepts discussed in this paper.
Results of the clinic simulation model described in Section 3.3 were pre-
sented as a poster at the 13th Conference on Retrovirals and Opportunistic 
Infections, February 6, 2006 and the 28th Annual Meeting of the Society for 
Medical Decision Making, October 2006.
References
1. WHO: Antiretroviral therapy for HIV infection in adults and
adolescents in resource-limited settings: towards universal
access.  Geneva , World Health Organization; 2006. 
2. WHO:  Towards universal access: scaling up priority HIV/
AIDS interventions in the health sector.  G e n e v a  ,  W o r l d
Health Organization; 2007. 
3. UNAIDS: AIDS epidemic update, December 2007.   [http://
data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf].
Accessed July 1, 2008Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Health Services Research 2008, 8:166 http://www.biomedcentral.com/1472-6963/8/166
Page 10 of 10
(page number not for citation purposes)
4. The Global Fund: Global Fund ARV Fact Sheet,.  2007 [http://
www.theglobalfund.org/en/files/publications/factsheets/aids/
ARV_Factsheet_2007.pdf]. Accessed July 1, 2008
5. Sepúlveda J, Carpenter C, Curran J, Holzemer W, Smits H, Scott K,
Orza N: PEPFAR implementation: progress and promise /
Committee for the Evaluation of the President’s Emergency
Plan for AIDS Relief (PEPFAR) Implementation, Board on
Global Health, Board on Children, Youth, and Families.
Washington, D.C. , Institute of Medicine; 2007:387. 
6. Taha HA: Operations Research: An Introduction.  6th edition.
New York , Prentice Hall; 1996. 
7. Bertozzi S, Gutierrez JP, Opuni M, Walker N, Schwartlander B: Esti-
mating resource needs for HIV/AIDS health care services in
low-income and middle-income countries.  Health Policy 2004,
69(2):189-200.
8. Kaplan EH, Merson MH: Allocating HIV-prevention resources:
balancing efficiency and equity.  Am J Public Health 2002,
92(12):1905-1907.
9. Rauner MS: Using simulation for AIDS policy modeling: bene-
fits for HIV/AIDS prevention policy makers in Vienna, Aus-
tria.  Health Care Manag Sci 2002, 5(2):121-134.
10. Zaric GS, Brandeau ML: A little planning goes a long way: mul-
tilevel allocation of HIV prevention resources.  Med Decis Mak-
ing 2007, 27(1):71-81.
11. Grant D, Lambert DM, Stock JR, Ellram LM: Fundamentals of
Logistics Management.   McGraw Hill Higher Education; 2005. 
12. WHO: Scaling up antiretroviral therapy in resource-limited
settings: treatment guidelines for a public health approach.
Geneva , World Health Organization; 2004. 
13. Harries AD, Schouten EJ, Makombe SD, Libamba E, Neufville HN,
Some E, Kadewere G, Lungu D: Ensuring uninterrupted supplies
of antiretroviral drugs in resource-poor settings: an example
from Malawi.  Bull World Health Organ 2007, 85(2):152-155.
14. Schechter M: Treatment at scale in Brazil: a physician's per-
spective.  Aids 2007, 21 Suppl 4:S31-5.
15. USAID: Guidelines for managing the HIV/AIDS supply chain.
Washington, D.C. ; 2006. 
16. Katabira ET, Oelrichs RB: Scaling up antiretroviral treatment in
resource-limited settings: success and challenges.  AIDS 2007,
21(suppl 4):S5-S10.
17. Houlihan JB: International supply chain management.  Interna-
tional Journal of Physical Distribution and Materials Management 1985,
15(1):22-38.
18. Jones TC, Riley DW: Using inventory for competitive advan-
tage through supply chain management.  International Journal of
Physical Distribution and Materials Management 1985, 15(5):16-26.
19. Landman KZ, Kinabo GD, Schimana W, Dolmans WM, Swai ME, Shao
JF, Crump JA: Capacity of health-care facilities to deliver HIV
treatment and care services, Northern Tanzania, 2004.  Int J
STD AIDS 2006, 17(7):459-462.
20. Martin R, Hearn TL, Ridderhof JC, Demby A: Implementation of a
quality systems approach for laboratory practice in
resource-constrained countries.  AIDS 2005, 19 Suppl 2:S59-65.
21. Donegan E, Moncada J, Chernesky M, Schachter J: Sexually trans-
mitted infection/HIV laboratory testing in resource-limited
countries: steps to improve use effective testing and to
ensure diagnostic capacity.  Sex Transm Dis 2003,
30(12):905-908.
22. Mullan F: The metrics of the physician brain drain.  N Engl J Med
2005, 353(17):1810-1818.
23. McCarthy EA, O'Brien ME, Rodriguez WR: Training and HIV-
treatment scale-up: establishing an implementation
research agenda.  PLoS Med 2006, 3(7):e304.
24. Fisher AA, Foreit JR: Designing HIV/AIDS intervention studies,
an operations research handbook.  New York, NY , The Popu-
lation Council Inc.; 2002. 
25. Wagner HM: Operations research: A global language for busi-
ness strategy.  Operations Research 1988, 36(5):797-803.
26. Earnshaw SR, Hicks K, Richter A, Honeycutt A: A linear program-
ming model for allocating HIV prevention funds with state
agencies: a pilot study.  Health Care Manag Sci 2007,
10(3):239-252.
27. Wilson D, Blower SM: Designing equitable antiretroviral allo-
cation strategies in resource-constrained countries.  PLoS Med
2005, 2(2):e50.
28. Bordoloi SK: Agent recruitment planning in knowledge-inten-
sive call centers.  Journal of Service Research 2004, 6(4):309-323.
29. Bordoloi SK, Matsuo H: Human resource planning in knowl-
edge-intensive operations: A model for learning with sto-
chastic turnover.  European Journal of Operational Research 2001,
130(1):169-189.
30. Grinold RC: Manpower planning with uncertain require-
ments.  Operations Research 1976, 24(3):387-399.
31. Schneider H, Blaauw D, Gilson L, Chabikuli N, Goudge J: Health sys-
tems and access to antiretroviral drugs for HIV in Southern
Africa: service delivery and human resources challenges.
Reprod Health Matters 2006, 14(27):12-23.
32. Klose A, Drexl A: Facility location models for distribution sys-
tem design.  European Journal of Operatiional Research 2005,
162(1):4-29.
33. Galarraga O, O'Brien ME, Gutierrez JP, Renaud-Thery F, Nguimfack
BD, Beusenberg M, Waldman K, Soni A, Bertozzi SM, Greener R:
Forecast of demand for antiretroviral drugs in low and mid-
dle-income countries: 2007-2008.  AIDS 2007, 21 Suppl
4:S97-103.
34. Consortium for Strategic HIV Operations Research (CSHOR): SIM-
CLIN Overview (Technical Report).  Boston, MA , Clinton
Foundation HIV/AIDS Initiative (CHAI); 2005. 
35. Lee HL: Material management in decentralized supply chains.
Operations Research 1993, 41(5):835-847.
36. Lee HL, So KC, S.Tang C: The value of information sharing in a
two-level supply chain.  Management Science 2000, 46(5):626-643.
37. O’Brien M, Xiong W, Hollingsworth E, Harlow J, Holstein C, Rod-
riguez W, Hupert N: Resource requirements for HIV ART
scale-up: A stochastic simulation model of a prototype HIV
clinic for resource-constrained settings.  In 13th Conference on
Retroviruses and Opportunistic Infections (CROI) Denver, Colorado ;
2006. 
38. Xiong W, O'Brien M, Hollingsworth EB, Rodriguez W, Hupert N:
Planning HIV treatment clinic scale-up in resource-limited
settings.  In 28th Annual Meeting of the Society for Medical Decision
Making Boston, MA ; 2006. 
39. Chung J, O’Brien M, Price J, Shumbusho F: Quantification of phy-
sician-time saved in a task shifting pilot program in Rwanda.
In 17th International AIDS Conference Mexico City, Mexico ; 2008. 
40. Cooper D, Cahn P, Lewin S, Kaldor J, McClure C, Kort R, Boyd M:
The Sydney Declaration: a call to scale up research.  Lancet
2007, 370(9581):7-8.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/8/166/pre
pub